{"gene":"MAP3K20","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2000,"finding":"MLTK (MAP3K20) was identified as a novel MAPKKK with two alternatively spliced isoforms, MLTKα and MLTKβ. Both isoforms activate ERK, JNK/SAPK, p38, and ERK5 pathways when overexpressed. Both are activated by osmotic shock via autophosphorylation. MLTKα (but not MLTKβ) expression disrupts actin stress fibers and causes morphological changes; a kinase-dead MLTKα does not, and p38 inhibition blocks these effects, placing p38 downstream of MLTKα in actin regulation.","method":"Overexpression in cells, kinase-dead mutant analysis, pharmacological p38 inhibition, SDS-PAGE mobility shift assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (overexpression, kinase-dead mutant, pharmacological inhibition) in a single lab; foundational characterization paper","pmids":["11042189"],"is_preprint":false},{"year":2000,"finding":"ZAK protein contains a kinase catalytic domain, a leucine-zipper, and a sterile-alpha motif (SAM), forms homodimers or oligomers in mammalian cells, and specifically activates the JNK/SAPK pathway and NF-κB transcription factor upon overexpression. Overexpression induces apoptosis in hepatoma cells.","method":"Cloning, overexpression in mammalian cells, Western blot for homodimerization/oligomerization, reporter assays for NF-κB and JNK/SAPK","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional readouts (dimerization, pathway activation, apoptosis) in a single lab with direct overexpression experiments","pmids":["10924358"],"is_preprint":false},{"year":2002,"finding":"ZAK activates JNK/SAPK via MKK7 but not MKK4: co-expression of dominant-negative MKK7 (but not dominant-negative MKK4) significantly attenuates ZAK-induced JNK/SAPK activation. ZAK expression (but not kinase-dead ZAK) disrupts actin stress fibers. ZAK expression increases the G2/M cell population and decreases cyclin E levels.","method":"Dominant-negative co-expression, kinase-dead mutant, Western blot for cyclin E, flow cytometry for cell cycle","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via dominant-negative constructs and kinase-dead mutant, single lab, multiple readouts","pmids":["12220515"],"is_preprint":false},{"year":2003,"finding":"PKNα phosphorylates MLTKα (MAP3K20) in vitro and this phosphorylation enhances MLTKα kinase activity. A kinase-negative PKNα mutant inhibits osmotic shock-induced MLTKα mobility shift. PKNα physically associates with MLTKα, MKK6, and p38γ, suggesting PKNα functions as both an upstream activator of MLTKα and a scaffold for the p38γ MAPK signaling pathway.","method":"In vitro kinase assay, kinase-negative mutant expression, co-immunoprecipitation, SDS-PAGE mobility shift","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus co-IP plus mutant analysis in single lab, multiple orthogonal methods establishing PKNα as writer/activator of MLTKα","pmids":["12761180"],"is_preprint":false},{"year":2003,"finding":"ZAK interacts with the novel zinc finger protein ZZaPK (identified by yeast two-hybrid). ZZaPK overexpression promotes cell re-entry into the cell cycle by increasing E2F expression and cyclin E/CDK2 activity, counteracting ZAK-mediated cell cycle arrest. ZAK is proposed to suppress ZZaPK function upstream.","method":"Yeast two-hybrid, co-expression studies, Western blot for E2F and cyclin E","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid interaction, single lab, limited functional validation of interaction mechanism","pmids":["12535642"],"is_preprint":false},{"year":2003,"finding":"The leucine zipper domain of MLK7 (MAP3K20) is required for full catalytic activity and is necessary for full pathway (JNK) activation: C-terminal deletion mutants lacking the leucine zipper retain only ~25% catalytic activity. However, sequence in residues 322–436 (beyond the leucine zipper) is necessary for full JNK pathway activation, as deletion of this region abolishes JNK activation.","method":"C-terminal deletion mutants, in vitro kinase assay for specific activity, co-transfection with JNK","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assays with nested deletion mutants, single lab, multiple constructs tested","pmids":["14521931"],"is_preprint":false},{"year":2004,"finding":"ZAK overexpression in H9c2 cardiomyoblast cells induces hypertrophic growth features including increased cell size, elevated atrial natriuretic factor (ANF) expression, and increased actin fiber organization, establishing ZAK as a positive mediator of cardiac hypertrophy.","method":"Overexpression in H9c2 cells, cell size measurement, ANF reporter/expression, actin staining","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct overexpression with multiple hypertrophy readouts, single lab","pmids":["15485649"],"is_preprint":false},{"year":2004,"finding":"TGF-β induces cardiac hypertrophy via a ZAK→MKK7→ANF signaling axis. Dominant-negative ZAK inhibits TGF-β-induced hypertrophic features (cell size, ANF expression, actin organization). Dominant-negative MKK7 blocks both TGF-β- and ZAK-induced ANF expression. JNK inhibitor SP600125 had little effect, distinguishing a JNK-independent MKK7-mediated pathway downstream of ZAK.","method":"Dominant-negative ZAK and MKK7 constructs, pharmacological JNK inhibitor, ANF expression assay, cell size measurement","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis by dominant-negative constructs and pharmacological inhibition, single lab, multiple readouts","pmids":["15465036"],"is_preprint":false},{"year":2004,"finding":"Transgenic mice with cardiac-specific overexpression of MLK7 (MAP3K20) develop myocardial fibrosis, hypertrophy, impaired systolic function, diastolic dysfunction, and increased mortality upon isoproterenol administration. Isoproterenol-induced activation of JNK and p38 (but not ERK) is significantly greater in MLK7 Tg mice, establishing that MLK7 simultaneously activates JNK and p38 in vivo in cardiac stress.","method":"Transgenic mouse generation, hemodynamic analysis, histology, Western blot for MAPK phosphorylation, isoproterenol challenge","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic model with cardiac-specific overexpression, multiple orthogonal readouts (hemodynamics, histology, signaling), clear phenotypic consequence","pmids":["15350844"],"is_preprint":false},{"year":2008,"finding":"ZAK (a ZAK isoform) is the MAP3K that transduces the ribotoxic stress response (RSR) from intoxicated ribosomes to SAPKinase activation following Shiga toxin 2 and ricin treatment. A ZAK-specific inhibitor (DHP-2) and siRNA knockdown of ZAK both diminish Stx2/ricin-induced SAPKinase activation and block upregulation of proinflammatory cytokine IL-8.","method":"ZAK-specific small molecule inhibitor (DHP-2), siRNA knockdown, Western blot for SAPK phosphorylation, IL-8 cytokine measurement","journal":"Cellular microbiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — two orthogonal loss-of-function approaches (inhibitor + siRNA) with multiple readouts (kinase activation, cytokine production, cell viability)","pmids":["18331592"],"is_preprint":false},{"year":2009,"finding":"RhoGDIβ physically interacts with ZAK and is phosphorylated by ZAK in vitro. This phosphorylation negatively regulates RhoGDIβ functions. Conversely, the ZAK–RhoGDIβ interaction maintains ZAK in an inactive hypophosphorylated form, revealing mutual negative regulation. ZAK knockdown in ZAK/RhoGDIβ co-expressing cells restores full RhoGDIβ function.","method":"Co-immunoprecipitation, in vitro kinase/phosphorylation assay, siRNA knockdown, Western blot","journal":"Journal of biomedical science","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation assay plus co-IP plus siRNA rescue, single lab, multiple orthogonal methods","pmids":["19272173"],"is_preprint":false},{"year":2009,"finding":"ZAK overexpression in H9c2 cells increases MMP-2 activity via JNK1/2 and p38 signaling, and reduces MMP-9 activity by increasing TIMP-1/2 expression, potentially contributing to cardiac fibrosis.","method":"Overexpression in H9c2 cells, zymography for MMP-2/9 activity, Western blot for TIMP-1/2, pathway inhibitor studies","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct overexpression with enzymatic activity readouts and pathway inhibitors, single lab","pmids":["19184368"],"is_preprint":false},{"year":2010,"finding":"ZAK is required for doxorubicin-induced SAPK activation and apoptosis in HaCaT keratinocytes (but not HeLa cells). siRNA-mediated knockdown of ZAK or ZAK inhibitors (sorafenib, nilotinib) block doxorubicin-induced proinflammatory and apoptotic responses, establishing ZAK as the upstream MAP3K in doxorubicin-triggered ribotoxic stress response.","method":"siRNA knockdown, pharmacological inhibition (sorafenib, nilotinib), Western blot for SAPK/ZAK, cell viability/apoptosis assays","journal":"Cancer biology & therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent loss-of-function methods (siRNA + two inhibitors) with multiple downstream readouts in defined cell contexts","pmids":["20559024"],"is_preprint":false},{"year":2010,"finding":"ZAK overexpression in lung cancer cells suppresses proliferation via ERK and JNK pathway activation in an AP-1-dependent manner. ZAK silencing reduces phospho-ERK and phospho-JNK without affecting p38. c-Jun RNAi reverses ZAK-mediated growth suppression and AP-1 activity. ZAK activates JNK→c-Jun and ERK→c-Fos to regulate AP-1.","method":"Overexpression, siRNA knockdown, ERK/JNK pathway inhibitors, AP-1 reporter (SEAP assay), c-Jun RNAi, Western blot, in vivo tumor xenograft","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple gain/loss-of-function approaches with pathway inhibitors and reporter assays, single lab","pmids":["20331627"],"is_preprint":false},{"year":2012,"finding":"MLTK (MAP3K20) plays an essential role in chondrogenesis by triggering Sox9-dependent induction of Sox6 expression. Knockdown of MLTK in Xenopus embryos causes loss of craniofacial cartilages without defects in neural crest development. Sox6 knockdown phenocopies MLTK knockdown. Ectopic MLTK expression induces Sox6 in a Sox9-dependent manner. p38 and JNK pathways function downstream of MLTK during chondrogenesis.","method":"Morpholino knockdown in Xenopus, ectopic expression, in situ hybridization, pharmacological p38/JNK inhibition","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockdown with phenotype, ectopic expression rescue, pathway epistasis, Sox9-dependency test, multiple orthogonal methods in Xenopus model","pmids":["22764049"],"is_preprint":false},{"year":2012,"finding":"ZAK is required for doxorubicin-induced activation of JNK and p38 MAPK in mouse primary macrophages. Using ZAK-deficient mouse macrophages, ZAK deficiency prevents doxorubicin-mediated phosphorylation of JNK and p38 and blocks expression of IL-1β, IL-6 and CXCL1. Nilotinib, ponatinib, and sorafenib suppress these effects pharmacologically.","method":"ZAK-deficient mouse macrophages (genetic KO), pharmacological inhibitors, Western blot for MAPK phosphorylation, qRT-PCR and ELISA for cytokines, in vivo co-administration in mice","journal":"Cancer biology & therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model plus pharmacological validation, in vitro and in vivo, multiple orthogonal readouts","pmids":["23114643"],"is_preprint":false},{"year":2013,"finding":"Sorafenib suppresses UV-induced apoptosis in cells by off-target inhibition of ZAK, thereby preventing ZAK-mediated JNK activation. This JNK suppression is independent of the ERK pathway, identifying ZAK inhibition as a mechanism of sorafenib adverse effects (cutaneous SCC development).","method":"Pharmacological inhibition, Western blot for JNK phosphorylation, apoptosis assays, comparison with ERK pathway","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological evidence with pathway-specific readouts, single lab, mechanistic claim supported by context-specific inhibition experiments","pmids":["24170769"],"is_preprint":false},{"year":2013,"finding":"ZAK activates MKK4 at the MAPKK level and is upstream of a ZAK→MKK4→JNK→TGFβ2 signaling cascade activated by the anticancer compound BA-TPQ in cancer cells but not normal cells.","method":"Phosphorylation analysis, pathway inhibitors (SP600125 for JNK, SD-208 for TGFβ), Western blot, mRNA quantification","journal":"Current cancer drug targets","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pharmacological pathway inference without direct biochemical reconstitution of ZAK→MKK4 step","pmids":["23607596"],"is_preprint":false},{"year":2015,"finding":"ZAK-mediated cardiomyocyte hypertrophy requires p38 and JNK pathway activation and nuclear translocation of GATA4 and c-Jun transcription factors, without involvement of ERK or NFATc3. A dominant-negative ZAK shows no effect on p38/JNK signaling. JNK1/2 and p38 inhibitors significantly suppress ZAK-induced BNP expression.","method":"Doxycycline-inducible Tet-on ZAK WT and DN expression systems, pathway inhibitors, Western blot for MAPK and transcription factors, nuclear translocation imaging","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible expression system with kinase-dead control plus pharmacological inhibitors, multiple pathway readouts, single lab","pmids":["25869677"],"is_preprint":false},{"year":2015,"finding":"ZAK (both isoforms ZAKα and ZAKβ) is a key factor in cancer cell migration. ZAK depletion reduces cell motility; overexpression activates ERK, JNK, and p38 and increases cell motion. Kinase-dead mutants ZAKα K45M and ZAKβ K45M act as dominant negatives, suppressing MAPK activation and migration. ZAK constitutes an essential element of the EGF/ERK-dependent cell migration pathway.","method":"siRNA knockdown, kinase-dead mutant overexpression, ZAK inhibitor (nilotinib), migration assays, Western blot for MAPK phosphorylation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple loss-of-function approaches (siRNA, kinase-dead, inhibitor), pathway readouts, single lab","pmids":["26522728"],"is_preprint":false},{"year":2016,"finding":"Crystal structure of ZAK kinase domain in complex with vemurafenib was solved, revealing a highly distorted P-loop conformation. Positional scanning peptide library analysis revealed unique substrate specificity with unprecedented preferences for histidine residues at positions -1 and +2 relative to the phosphoacceptor site.","method":"X-ray crystallography (co-crystal structure), positional scanning peptide library, clinical kinase inhibitor library screen","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional substrate specificity profiling, single study with multiple orthogonal methods","pmids":["26999302"],"is_preprint":false},{"year":2016,"finding":"Loss-of-function mutations in the SAM domain of ZAK cause split-foot defects in humans. CRISPR/Cas9-mediated knockout of both Zak isoforms is embryonically lethal in mice, while SAM domain deletion induces complex hindlimb defects associated with down-regulation of Trp63 (a known SHFM disease gene), placing ZAK upstream of Trp63 in limb patterning.","method":"Human genetic analysis, CRISPR/Cas9 knockout/deletion in mouse, in situ hybridization for Zak expression in limbs, transcriptome analysis for Trp63","journal":"Genome research","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO mouse model with domain-specific deletion, genetic epistasis via Trp63 downregulation, replication in two human families","pmids":["26755636"],"is_preprint":false},{"year":2016,"finding":"In a novel ZAK knockout mouse, ricin-intoxicated macrophages from zak-/- mice fail to activate p38 and JNK1/2 and show decreased c-jun and cxcl-1 expression compared to wild-type. zak-/- mice show decreased duodenal damage following in vivo ricin challenge, confirming ZAK's essential role in the ribotoxic stress response in vivo.","method":"ZAK knockout mouse, Western blot for p38/JNK activation, qRT-PCR, blinded histopathology of duodenal tissue","journal":"Toxins","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with in vitro and in vivo phenotypic readouts, blinded histopathology, multiple molecular endpoints","pmids":["27598200"],"is_preprint":false},{"year":2016,"finding":"ZAK (MRK) protects tumor cells from radiation-induced cell death by regulating cell-cycle arrest after ionizing radiation. siRNA depletion of ZAK sensitizes medulloblastoma cells to radiation. A ZAK-specific irreversible small molecule inhibitor (M443) inhibits radiation-induced activation of p38 and Chk2 (downstream of ZAK) and radiosensitizes tumor cells but not normal brain cells.","method":"siRNA knockdown, small molecule ZAK inhibitor (M443, irreversible), Western blot for p38/Chk2, cell viability, orthotopic animal model","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological inhibition with pathway readouts, in vivo model, single lab","pmids":["27207779"],"is_preprint":false},{"year":2016,"finding":"ZAK kinase activity is required for canonical TGF-β/SMAD-dependent signaling: siRNA depletion of ZAK strongly inhibits TGF-β-dependent SMAD2/3 phosphorylation and SMAD binding element-driven luciferase activity. A ZAK inhibitor (DHP-2) dose-dependently activates a TGFβR-kinase activity reporter, blocks TGF-β-induced SMAD2/3 phosphorylation, and inhibits cancer cell invasion.","method":"siRNA knockdown, pharmacological ZAK inhibitor (DHP-2), bioluminescent kinase reporter (BTR), SMAD2/3 phosphorylation assay, SBE4-Luc reporter, invasion assay","journal":"Translational oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological inhibitor with multiple pathway readouts, single lab, two orthogonal loss-of-function methods","pmids":["27783979"],"is_preprint":false},{"year":2018,"finding":"ZAK-mediated EMT is associated with activation of ZEB1, suppression of epithelial splicing regulatory proteins (ESRPs), and a switch in CD44 isoform expression from epithelial CD44v8-9 to mesenchymal CD44s. ZAK depletion in mesenchymal cancer cells reverses EMT, increases drug sensitivity, and attenuates bone metastasis.","method":"cDNA overexpression screen, ZAK depletion (siRNA/shRNA), Western blot for EMT markers, CD44 isoform analysis, bone metastasis assay, transcriptomics","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain and loss of function with mechanistic readouts (ZEB1, ESRPs, CD44 isoform switch), single lab","pmids":["29396440"],"is_preprint":false},{"year":2018,"finding":"ERβ directly binds ZAK under normal conditions (interaction shown by co-IP). ZAK overexpression reduces ZAK-ERβ association. ERβ overexpression blocks ZAK nuclear translocation via inhibition of SUMO-1 modification of ZAK, and suppresses ZAK-induced p-JNK, p-p38, c-Jun, and GATA-4 upregulation.","method":"Co-immunoprecipitation, transient transfection, Western blot for SUMO-1 modification, nuclear fractionation/localization assay","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP for direct interaction, SUMO-1 modification analysis, nuclear localization assay, single lab","pmids":["29932238"],"is_preprint":false},{"year":2018,"finding":"ZAKβ isoform has antitumorigenic properties opposite to ZAKα. High ZAKβ:ZAKα ratio activates cAMP/CREB1 signaling, reduces cyclooxygenase 2 and β-catenin, and inhibits anchorage-independent growth. Doxorubicin treatment switches endogenous expression from ZAKα to ZAKβ.","method":"Isoform-specific overexpression, soft agar anchorage-independent growth assay, Western blot, cAMP reporter assay, doxorubicin treatment","journal":"The Chinese journal of physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific overexpression with functional and signaling readouts, single lab","pmids":["29374956"],"is_preprint":false},{"year":2022,"finding":"Upon ribosome impairment (Rptor deletion, amino acid starvation, or low-dose cycloheximide), intestinal stem cells gain an Lgr5-negative fetal-like identity requiring ZAKα activation. Mechanistically, ZAKα activates YAP via SRC kinase to mediate this stem cell identity switch. ZAKα is thus identified as a critical mediator of ISC plasticity downstream of ribosome stress.","method":"Mouse intestinal organoids, conditional mouse knockouts, pharmacological ribosome impairment, Western blot for ZAKα/YAP/SRC, ISC identity markers (Lgr5, fetal markers), metabolic profiling","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple ribosome impairment methods, mouse and organoid models, pathway epistasis (ZAKα→SRC→YAP), mechanistic and phenotypic readouts, replicated across perturbations","pmids":["35918345"],"is_preprint":false},{"year":2022,"finding":"ZAK overexpression in fibrotic kidney is in complex with Smad2/3 and TGF-β receptor I (TβRI). Silencing ZAK reduces Smad2/3 recruitment to TβRI and attenuates p38 MAPK and Smad signaling, reducing tubulointerstitial fibrosis in vivo.","method":"Co-immunoprecipitation of ZAK-Smad2/3-TβRI complex, ZAK siRNA knockdown, UUO mouse model, Western blot, pharmacological ZAK inhibitor (6p)","journal":"Translational research : the journal of laboratory and clinical medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP establishes complex membership, siRNA and inhibitor loss-of-function with in vivo validation, single lab","pmids":["35276386"],"is_preprint":false},{"year":2023,"finding":"ZAKβ isoform is the only isoform expressed in skeletal muscle and is activated by muscle contraction and cellular compression. Phosphoproteomics identified SYNPO2, BAG3, and Filamin C (FLNC) as ZAKβ substrates/interactors. ZAK deficiency leads to accumulation of mislocalized FLNC and BAG3 in muscle fibers, with exacerbation by endogenous muscle overloading, establishing ZAKβ as necessary for adaptive turnover of FLNC in response to mechanical stress.","method":"Phosphoproteomics, ZAK-deficient mice and zebrafish, immunofluorescence of human biopsy and mouse muscle, overloading model, histopathology","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics plus genetic KO in multiple organisms plus human biopsy, single lab, multiple orthogonal methods","pmids":["37427997"],"is_preprint":false},{"year":2025,"finding":"Cryo-EM and biochemistry revealed that ZAK is constitutively recruited to ribosomes and, upon ribosome collisions, interactions between ZAK and ribosomal protein RACK1 enable activation by dimerization of its SAM domains at the collision interface. SERBP1, a ribosome-binding protein, negatively regulates ZAK by preventing constitutive activation. SAM domain variants (including a known pathogenic variant) can bypass the ribosome requirement for ZAK activation, confirming the SAM domain's key role in regulating kinase activity on and off the ribosome.","method":"Cryo-electron microscopy, biochemical reconstitution, SAM domain mutagenesis, co-immunoprecipitation for RACK1 and SERBP1 interactions","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure plus biochemical reconstitution plus mutagenesis, multiple orthogonal methods, establishes mechanistic blueprint for ZAK activation","pmids":["41261136"],"is_preprint":false},{"year":2026,"finding":"BCR::ABL1 inhibition in CML cells induces ribosome collisions, generating collided ribosomes that trigger ZAK-dependent p38 activation and apoptosis. Mechanistically, BCR::ABL1 inhibition activates the mTOR-EEF2K pathway to phosphorylate EEF2, slowing translation elongation and generating nuclease-resistant collided ribosomes upstream of ZAK. Loss of ZAK function reduces the cytotoxic effects of BCR::ABL1 inhibitors.","method":"ZAK loss-of-function (siRNA/CRISPR), ribosome profiling/nuclease protection assay for collided ribosomes, Western blot for p38/EEF2 phosphorylation, primary CML patient cells, pharmacological translation modulation","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic ZAK loss-of-function, ribosome collision biochemical assay, patient primary cells, mechanistic pathway defined (mTOR-EEF2K-EEF2→ribosome collision→ZAK→p38→apoptosis)","pmids":["41912913"],"is_preprint":false},{"year":2026,"finding":"GCN2iB, widely used as a GCN2/ISR inhibitor, is a direct inhibitor of ZAK kinase. Biochemical measurements, cell-based assays, and structural modeling demonstrate that GCN2iB inhibits ZAK, dampening stress-induced JNK and p38 activation. This off-target ZAK inhibition masks cytotoxic consequences normally associated with GCN2 inhibition.","method":"Biochemical kinase assay, cell-based MAPK phosphorylation assays, structural modeling","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct biochemical inhibition assay plus structural modeling plus cell-based validation, single study","pmids":["42031169"],"is_preprint":false},{"year":2025,"finding":"ZAKα dynamically monitors the mRNA exit channel of elongating ribosomes for mRNA stasis via direct interactions with ribosomal proteins RACK1 and RPS27 and with 18S rRNA helix-26. Four mRNA-binding peptides in ZAKα span across the path of ribosome-exiting mRNA. Progressive elongation threads ZAKα off the ribosome, while mRNA stasis stabilizes the interaction. Prolonged binding is associated with sequestration of the inhibitory SAM domain on RACK1, allowing transient ZAKα dimerization, activation loop trans-autophosphorylation, and RSR activation.","method":"AlphaFold3 structural prediction, RNA crosslinking and immunoprecipitation (CLIP), biochemical interaction mapping, mutagenesis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — CLIP plus structural prediction plus mutagenesis, preprint not yet peer-reviewed, but orthogonal to and consistent with published cryo-EM data","pmids":[],"is_preprint":true}],"current_model":"MAP3K20 (ZAK/MLTK) is a MAP kinase kinase kinase with two isoforms (ZAKα/MLTKα and ZAKβ/MLTKβ) that functions as a central sensor of ribotoxic stress: ZAKα is constitutively recruited to elongating ribosomes via RACK1 and RPS27 interactions and is activated by SAM-domain dimerization at ribosome collision interfaces (negatively regulated by SERBP1), whereupon it phosphorylates and activates downstream MAPKs p38 and JNK (via MKK7 preferentially) to drive proinflammatory cytokine production, apoptosis, cell cycle arrest, and stem cell identity changes; it also regulates cardiac hypertrophy (via p38/JNK→GATA4/c-Jun), chondrogenesis (via p38/JNK→Sox6 induction), cell migration (via ERK/JNK), EMT (via ZEB1/ESRP/CD44 isoform switching), and TGF-β canonical signaling (by forming a complex with Smad2/3 and TβRI), while ZAKβ is the mechanosensitive isoform in skeletal muscle that mediates adaptive turnover of Filamin C under mechanical stress."},"narrative":{"mechanistic_narrative":"MAP3K20 (ZAK/MLTK) is a MAP kinase kinase kinase that operates as the central sensor of ribotoxic stress, transducing damage at the ribosome to stress-activated MAPK output [PMID:18331592]. The protein is expressed as two alternatively spliced isoforms (ZAKα/MLTKα and ZAKβ/MLTKβ) that activate JNK/SAPK, p38, ERK and NF-κB and are activated by osmotic shock through autophosphorylation [PMID:11042189, PMID:10924358]. Its architecture—kinase domain, leucine zipper required for full catalytic activity, and a sterile-alpha (SAM) domain mediating homo-oligomerization—defines its activation logic [PMID:10924358, PMID:14521931]. ZAKα is constitutively recruited to elongating ribosomes through interactions with RACK1, RPS27 and 18S rRNA, monitoring the mRNA exit channel; ribosome collisions promote SAM-domain dimerization at the collision interface, trans-autophosphorylation, and ribotoxic stress response activation, a step negatively regulated by SERBP1, while pathogenic SAM-domain variants bypass the ribosome requirement [PMID:41261136]. Downstream, ZAK preferentially routes JNK activation through MKK7 and simultaneously activates p38 in vivo, driving proinflammatory cytokine production (IL-8, IL-1β, IL-6, CXCL1), apoptosis, and cell-cycle arrest in response to ribotoxic insults including Shiga toxin, ricin and doxorubicin [PMID:12220515, PMID:15350844, PMID:18331592, PMID:23114643, PMID:27598200]. Beyond stress sensing, ZAK acts as a positive mediator of cardiac hypertrophy and fibrosis via p38/JNK→GATA4/c-Jun [PMID:15465036, PMID:15350844, PMID:25869677], is essential for chondrogenesis through Sox9-dependent Sox6 induction [PMID:22764049], promotes cancer cell migration, EMT and invasion [PMID:26522728, PMID:29396440], and participates in canonical TGF-β/SMAD signaling by complexing with Smad2/3 and TβRI [PMID:27783979, PMID:35276386]. The ZAKβ isoform is the mechanosensitive species in skeletal muscle, activated by contraction and compression and required for adaptive turnover of Filamin C with BAG3 and SYNPO2 under mechanical stress [PMID:37427997]. Loss-of-function SAM-domain mutations cause human split-foot/limb defects, placing ZAK upstream of Trp63 in limb patterning [PMID:26755636].","teleology":[{"year":2000,"claim":"Establishing that MAP3K20 is a genuine MAP3K answered whether a new node feeds the stress MAPK network; it defined two isoforms and their upstream-kinase behavior.","evidence":"cloning, overexpression with kinase-dead mutants, and pharmacological p38 inhibition in mammalian cells","pmids":["11042189","10924358"],"confidence":"Medium","gaps":["Activation relied on overexpression, not endogenous stimuli","Physiological activating signals beyond osmotic shock unknown","Isoform-specific functions not resolved"]},{"year":2002,"claim":"Defining the immediate downstream MAPKK answered how ZAK channels JNK activation and linked it to cell-cycle control.","evidence":"dominant-negative MKK7 vs MKK4 epistasis, kinase-dead mutant, flow cytometry and cyclin E blots","pmids":["12220515"],"confidence":"Medium","gaps":["MKK7 specificity tested only by dominant-negative, not direct phosphorylation","Mechanism of G2/M arrest not defined"]},{"year":2003,"claim":"Identifying PKNα as a direct activator/scaffold addressed how ZAK kinase activity is itself regulated upstream.","evidence":"in vitro kinase assay, kinase-negative PKNα, and co-IP of MLTKα/MKK6/p38γ","pmids":["12761180","14521931"],"confidence":"High","gaps":["Whether PKNα regulation operates at endogenous levels untested","Relationship of PKNα input to ribotoxic activation unknown"]},{"year":2008,"claim":"Placing ZAK as the MAP3K of the ribotoxic stress response answered what kinase couples damaged ribosomes to SAPK and cytokine output—its defining role.","evidence":"ZAK-specific inhibitor and siRNA after Shiga toxin/ricin, with SAPK and IL-8 readouts","pmids":["18331592"],"confidence":"High","gaps":["How damaged ribosomes are physically sensed not yet defined","Direct ribosome interaction not shown at this stage"]},{"year":2010,"claim":"Extending ribotoxic stress to chemotherapy and context dependence clarified when ZAK governs apoptosis versus proliferation.","evidence":"siRNA and multiple inhibitors in keratinocytes vs HeLa; ERK/JNK/AP-1 readouts and xenografts in lung cancer cells","pmids":["20559024","20331627"],"confidence":"Medium","gaps":["Cell-type basis of opposing outcomes unexplained","Direct substrates of ERK vs JNK branches not mapped"]},{"year":2015,"claim":"Defining the cardiac and migration outputs answered what physiological processes ZAK MAPK signaling drives beyond stress.","evidence":"inducible WT/dominant-negative ZAK, kinase-dead mutants, pathway inhibitors, transgenic and H9c2 systems","pmids":["25869677","26522728","15350844","15465036"],"confidence":"High","gaps":["Mechanistic link between ribotoxic sensing and cardiac/migration roles unclear","Endogenous activating signal in cardiomyocytes undefined"]},{"year":2016,"claim":"Structural and genetic work answered both the catalytic basis of ZAK substrate selection and its in vivo developmental requirement.","evidence":"kinase-domain crystal structure with peptide-library specificity profiling, and CRISPR SAM-deletion mice with human SHFM family genetics linking ZAK upstream of Trp63","pmids":["26999302","26755636","27598200","22764049"],"confidence":"High","gaps":["Physiological substrates matching the histidine-preference motif not identified","How SAM-domain loss perturbs limb patterning at the signaling level unresolved"]},{"year":2018,"claim":"Resolving isoform divergence and EMT control answered why ZAKα and ZAKβ can produce opposing tumor phenotypes.","evidence":"isoform-specific overexpression, soft-agar growth, ZEB1/ESRP/CD44 isoform analysis, and ERβ co-IP/SUMO-1 modulation of nuclear translocation","pmids":["29396440","29374956","29932238"],"confidence":"Medium","gaps":["Molecular determinant of ZAKα vs ZAKβ output not defined","Direct effectors of EMT splicing switch unknown"]},{"year":2022,"claim":"Linking ZAKα to ribosome-stress-driven stem cell plasticity and TGF-β fibrosis expanded the downstream physiology of the ribotoxic sensor.","evidence":"intestinal organoids/conditional KO with ZAKα→SRC→YAP epistasis, and ZAK–Smad2/3–TβRI co-IP with UUO mouse model","pmids":["35918345","35276386"],"confidence":"High","gaps":["How ribosome stress is decoded into a YAP versus MAPK output unclear","Direct phosphorylation events in the SMAD complex not mapped"]},{"year":2023,"claim":"Defining ZAKβ as the muscle mechanosensor answered the distinct physiological function of the second isoform.","evidence":"phosphoproteomics identifying SYNPO2/BAG3/FLNC, ZAK-deficient mice and zebrafish, and human biopsy immunofluorescence with overloading","pmids":["37427997"],"confidence":"Medium","gaps":["Direct phosphorylation of FLNC not biochemically confirmed","How mechanical force activates ZAKβ mechanistically unknown"]},{"year":2025,"claim":"Cryo-EM and channel-monitoring models answered the long-standing question of how ZAKα physically senses ribosome collisions and mRNA stasis to trigger activation.","evidence":"cryo-EM, biochemical reconstitution and SAM mutagenesis (RACK1/SERBP1); plus CLIP and AlphaFold3 mapping of RACK1/RPS27/18S helix-26 contacts (preprint)","pmids":["41261136"],"confidence":"High","gaps":["How collision-driven dimerization is timed and reversed not fully defined","Quantitative threshold of collisions required for activation unknown"]},{"year":2026,"claim":"Connecting oncogene inhibition to ribosome collisions and clarifying inhibitor off-target effects refined the therapeutic logic of ZAK targeting.","evidence":"ZAK loss-of-function with ribosome collision assays in CML cells defining mTOR-EEF2K-EEF2→collision→ZAK→p38; biochemical and structural demonstration that GCN2iB directly inhibits ZAK","pmids":["41912913","42031169"],"confidence":"High","gaps":["Generality of collision-driven ZAK cytotoxicity across drug classes untested","Selectivity of clinical ZAK inhibitors incompletely characterized"]},{"year":null,"claim":"How the same ribosome-collision-activated kinase is wired to such divergent outputs—cytokine/apoptosis, cardiac hypertrophy, chondrogenesis, EMT, stem-cell identity, and muscle mechanostructural turnover—remains the central open question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Physiological direct substrates beyond MAPKKs largely unidentified","Determinants selecting downstream output by cell type and isoform unknown","Activation mechanism of ZAKβ mechanosensing not structurally defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,3,9,20]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,5,20]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[9,31,34]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[20]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[9,31,34]}],"localization":[{"term_id":"GO:0005840","term_label":"ribosome","supporting_discovery_ids":[31,34]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,9]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[26]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,9,24]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[9,31,32]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[31,32,34]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,12,32]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[14,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,15,22]}],"complexes":["ZAK-Smad2/3-TβRI complex","ribosome (ZAKα-RACK1-RPS27)"],"partners":["RACK1","RPS27","SERBP1","MKK7","PKNΑ","SMAD2/3","ESR2","FLNC"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NYL2","full_name":"Mitogen-activated protein kinase kinase kinase 20","aliases":["Human cervical cancer suppressor gene 4 protein","HCCS-4","Leucine zipper- and sterile alpha motif-containing kinase","MLK-like mitogen-activated protein triple kinase","Mitogen-activated protein kinase kinase kinase MLT","Mixed lineage kinase 7","Mixed lineage kinase-related kinase","MLK-related kinase","MRK","Sterile alpha motif- and leucine zipper-containing kinase AZK"],"length_aa":800,"mass_kda":91.2,"function":"Stress-activated component of a protein kinase signal transduction cascade that promotes programmed cell death in response to various stress, such as ribosomal stress, osmotic shock and ionizing radiation (PubMed:10924358, PubMed:11836244, PubMed:12220515, PubMed:14521931, PubMed:15350844, PubMed:15737997, PubMed:18331592, PubMed:20559024, PubMed:26999302, PubMed:32289254, PubMed:32610081, PubMed:35857590). Acts by catalyzing phosphorylation of MAP kinase kinases, leading to activation of the JNK (MAPK8/JNK1, MAPK9/JNK2 and/or MAPK10/JNK3) and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways (PubMed:11042189, PubMed:11836244, PubMed:12220515, PubMed:14521931, PubMed:15172994, PubMed:15737997, PubMed:32289254, PubMed:32610081, PubMed:35857590). Activates JNK through phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7, and MAP kinase p38 gamma (MAPK12) via phosphorylation of MAP2K3/MKK3 and MAP2K6/MKK6 (PubMed:11836244, PubMed:12220515). Involved in stress associated with adrenergic stimulation: contributes to cardiac decompensation during periods of acute cardiac stress (PubMed:15350844, PubMed:21224381, PubMed:27859413). May be involved in regulation of S and G2 cell cycle checkpoint by mediating phosphorylation of CHEK2 (PubMed:15342622) Key component of the stress-activated protein kinase signaling cascade in response to ribotoxic stress or UV-B irradiation (PubMed:32289254, PubMed:32610081, PubMed:35857590). Acts as the proximal sensor of ribosome collisions during the ribotoxic stress response (RSR): directly binds to the ribosome by inserting its flexible C-terminus into the ribosomal intersubunit space, thereby acting as a sentinel for colliding ribosomes (PubMed:32289254, PubMed:32610081). Upon ribosome collisions, activates either the stress-activated protein kinase signal transduction cascade or the integrated stress response (ISR), leading to programmed cell death or cell survival, respectively (PubMed:32610081). Dangerous levels of ribosome collisions trigger the autophosphorylation and activation of MAP3K20, which dissociates from colliding ribosomes and phosphorylates MAP kinase kinases, leading to activation of the JNK and MAP kinase p38 pathways that promote programmed cell death (PubMed:32289254, PubMed:32610081). Less dangerous levels of ribosome collisions trigger the integrated stress response (ISR): MAP3K20 activates EIF2AK4/GCN2 independently of its protein-kinase activity, promoting EIF2AK4/GCN2-mediated phosphorylation of EIF2S1/eIF-2-alpha (PubMed:32610081). Also part of the stress-activated protein kinase signaling cascade triggering the NLRP1 inflammasome in response to UV-B irradiation: ribosome collisions activate MAP3K20, which directly phosphorylates NLRP1, leading to activation of the NLRP1 inflammasome and subsequent pyroptosis (PubMed:35857590). NLRP1 is also phosphorylated by MAP kinase p38 downstream of MAP3K20 (PubMed:35857590). Also acts as a histone kinase by phosphorylating histone H3 at 'Ser-28' (H3S28ph) (PubMed:15684425) Isoform that lacks the C-terminal region that mediates ribosome-binding: does not act as a sensor of ribosome collisions in response to ribotoxic stress (PubMed:32289254, PubMed:32610081, PubMed:35857590). May act as an antagonist of isoform ZAKalpha: interacts with isoform ZAKalpha, leading to decrease the expression of isoform ZAKalpha (PubMed:27859413)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NYL2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAP3K20","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PSPC1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/MAP3K20","total_profiled":1310},"omim":[{"mim_id":"617760","title":"MYOPATHY, CENTRONUCLEAR, 6, WITH FIBER-TYPE DISPROPORTION; CNM6","url":"https://www.omim.org/entry/617760"},{"mim_id":"616890","title":"SPLIT-FOOT MALFORMATION WITH MESOAXIAL POLYDACTYLY; SFMMP","url":"https://www.omim.org/entry/616890"},{"mim_id":"609479","title":"MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 20; MAP3K20","url":"https://www.omim.org/entry/609479"},{"mim_id":"606636","title":"NLR FAMILY, PYRIN DOMAIN-CONTAINING 1; NLRP1","url":"https://www.omim.org/entry/606636"},{"mim_id":"600289","title":"MITOGEN-ACTIVATED PROTEIN KINASE 14; MAPK14","url":"https://www.omim.org/entry/600289"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":245.3},{"tissue":"tongue","ntpm":261.1}],"url":"https://www.proteinatlas.org/search/MAP3K20"},"hgnc":{"alias_symbol":["MLTKalpha","MLTKbeta","ZAK","MLTK","MLK7","MRK"],"prev_symbol":[]},"alphafold":{"accession":"Q9NYL2","domains":[{"cath_id":"3.30.200.20","chopping":"2-85","consensus_level":"medium","plddt":83.288,"start":2,"end":85},{"cath_id":"1.10.510.10","chopping":"89-290","consensus_level":"high","plddt":91.2266,"start":89,"end":290},{"cath_id":"1.10.150.50","chopping":"337-416","consensus_level":"high","plddt":81.094,"start":337,"end":416},{"cath_id":"2.60.40.1970","chopping":"434-552","consensus_level":"high","plddt":82.1615,"start":434,"end":552}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYL2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYL2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYL2-F1-predicted_aligned_error_v6.png","plddt_mean":68.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAP3K20","jax_strain_url":"https://www.jax.org/strain/search?query=MAP3K20"},"sequence":{"accession":"Q9NYL2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NYL2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NYL2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYL2"}},"corpus_meta":[{"pmid":"11042189","id":"PMC_11042189","title":"Identification and characterization of a novel MAP kinase kinase kinase, MLTK.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11042189","citation_count":97,"is_preprint":false},{"pmid":"25013376","id":"PMC_25013376","title":"Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma.","date":"2014","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25013376","citation_count":94,"is_preprint":false},{"pmid":"10924358","id":"PMC_10924358","title":"Cloning and expression of ZAK, a mixed lineage kinase-like protein containing a leucine-zipper and a sterile-alpha motif.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10924358","citation_count":88,"is_preprint":false},{"pmid":"18331592","id":"PMC_18331592","title":"ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression.","date":"2008","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18331592","citation_count":87,"is_preprint":false},{"pmid":"24807215","id":"PMC_24807215","title":"Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24807215","citation_count":76,"is_preprint":false},{"pmid":"30249278","id":"PMC_30249278","title":"Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30249278","citation_count":61,"is_preprint":false},{"pmid":"26755636","id":"PMC_26755636","title":"Exome sequencing and CRISPR/Cas genome editing identify mutations of ZAK as a cause of limb defects in humans and mice.","date":"2016","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/26755636","citation_count":52,"is_preprint":false},{"pmid":"23114643","id":"PMC_23114643","title":"Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.","date":"2012","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23114643","citation_count":51,"is_preprint":false},{"pmid":"20559024","id":"PMC_20559024","title":"ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells.","date":"2010","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20559024","citation_count":49,"is_preprint":false},{"pmid":"12220515","id":"PMC_12220515","title":"Mixed lineage kinase ZAK utilizing MKK7 and not MKK4 to activate the c-Jun N-terminal kinase and playing a role in the cell arrest.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12220515","citation_count":36,"is_preprint":false},{"pmid":"20331627","id":"PMC_20331627","title":"ZAK inhibits human lung cancer cell growth via ERK and JNK activation in an AP-1-dependent manner.","date":"2010","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/20331627","citation_count":34,"is_preprint":false},{"pmid":"26522728","id":"PMC_26522728","title":"The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26522728","citation_count":32,"is_preprint":false},{"pmid":"31312514","id":"PMC_31312514","title":"Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer.","date":"2019","source":"NPJ systems biology and applications","url":"https://pubmed.ncbi.nlm.nih.gov/31312514","citation_count":30,"is_preprint":false},{"pmid":"15485649","id":"PMC_15485649","title":"ZAK re-programs atrial natriuretic factor expression and induces hypertrophic growth in H9c2 cardiomyoblast cells.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15485649","citation_count":29,"is_preprint":false},{"pmid":"25869677","id":"PMC_25869677","title":"ZAK induces cardiomyocyte hypertrophy and brain natriuretic peptide expression via p38/JNK signaling and GATA4/c-Jun transcriptional factor activation.","date":"2015","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25869677","citation_count":27,"is_preprint":false},{"pmid":"27816943","id":"PMC_27816943","title":"Recessive mutations in the kinase ZAK cause a congenital myopathy with fibre type disproportion.","date":"2016","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27816943","citation_count":27,"is_preprint":false},{"pmid":"19740035","id":"PMC_19740035","title":"Molecular mapping of a stripe rust resistance gene in spring wheat cultivar Zak.","date":"2009","source":"Phytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19740035","citation_count":27,"is_preprint":false},{"pmid":"12761180","id":"PMC_12761180","title":"Regulation of a mitogen-activated protein kinase kinase kinase, MLTK by PKN.","date":"2003","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12761180","citation_count":26,"is_preprint":false},{"pmid":"35918345","id":"PMC_35918345","title":"Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35918345","citation_count":26,"is_preprint":false},{"pmid":"24170769","id":"PMC_24170769","title":"Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24170769","citation_count":26,"is_preprint":false},{"pmid":"15465036","id":"PMC_15465036","title":"Transforming growth factor-beta induces the expression of ANF and hypertrophic growth in cultured cardiomyoblast cells through ZAK.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15465036","citation_count":26,"is_preprint":false},{"pmid":"23162799","id":"PMC_23162799","title":"Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor imatinib.","date":"2012","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/23162799","citation_count":25,"is_preprint":false},{"pmid":"29428732","id":"PMC_29428732","title":"Knockdown of long non-coding RNA MAP3K20 antisense RNA 1 inhibits gastric cancer growth through epigenetically regulating miR-375.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29428732","citation_count":24,"is_preprint":false},{"pmid":"31044527","id":"PMC_31044527","title":"Fisetin activates Hippo pathway and JNK/ERK/AP-1 signaling to inhibit proliferation and induce apoptosis of human osteosarcoma cells via ZAK overexpression.","date":"2019","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/31044527","citation_count":23,"is_preprint":false},{"pmid":"19184368","id":"PMC_19184368","title":"ZAK induces MMP-2 activity via JNK/p38 signals and reduces MMP-9 activity by increasing TIMP-1/2 expression in H9c2 cardiomyoblast cells.","date":"2009","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19184368","citation_count":23,"is_preprint":false},{"pmid":"28586211","id":"PMC_28586211","title":"Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.","date":"2017","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28586211","citation_count":23,"is_preprint":false},{"pmid":"26999302","id":"PMC_26999302","title":"Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib.","date":"2016","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/26999302","citation_count":22,"is_preprint":false},{"pmid":"31244114","id":"PMC_31244114","title":"Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31244114","citation_count":21,"is_preprint":false},{"pmid":"12535642","id":"PMC_12535642","title":"A novel zinc finger protein, ZZaPK, interacts with ZAK and stimulates the ZAK-expressing cells re-entering the cell cycle.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12535642","citation_count":19,"is_preprint":false},{"pmid":"29396440","id":"PMC_29396440","title":"Mixed lineage kinase ZAK promotes epithelial-mesenchymal transition in cancer progression.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29396440","citation_count":18,"is_preprint":false},{"pmid":"23212773","id":"PMC_23212773","title":"Increased ABA sensitivity results in higher seed dormancy in soft white spring wheat cultivar 'Zak'.","date":"2012","source":"TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik","url":"https://pubmed.ncbi.nlm.nih.gov/23212773","citation_count":17,"is_preprint":false},{"pmid":"15350844","id":"PMC_15350844","title":"Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic beta-adrenergic stimulation.","date":"2004","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15350844","citation_count":14,"is_preprint":false},{"pmid":"33188210","id":"PMC_33188210","title":"Long-range ballistic transport of Brown-Zak fermions in graphene superlattices.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33188210","citation_count":13,"is_preprint":false},{"pmid":"22764049","id":"PMC_22764049","title":"The protein kinase MLTK regulates chondrogenesis by inducing the transcription factor Sox6.","date":"2012","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22764049","citation_count":12,"is_preprint":false},{"pmid":"29932238","id":"PMC_29932238","title":"ERβ targets ZAK and attenuates cellular hypertrophy via SUMO-1 modification in H9c2 cells.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29932238","citation_count":11,"is_preprint":false},{"pmid":"19538723","id":"PMC_19538723","title":"ZAK negatively regulates RhoGDIbeta-induced Rac1-mediated hypertrophic growth and cell migration.","date":"2009","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/19538723","citation_count":11,"is_preprint":false},{"pmid":"41261136","id":"PMC_41261136","title":"ZAK activation at the collided ribosome.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/41261136","citation_count":10,"is_preprint":false},{"pmid":"30535460","id":"PMC_30535460","title":"Long non‑coding RNA MLK7‑AS1 promotes proliferation in human colorectal cancer via downregulation of p21 expression.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30535460","citation_count":10,"is_preprint":false},{"pmid":"29071797","id":"PMC_29071797","title":"Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer.","date":"2017","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29071797","citation_count":9,"is_preprint":false},{"pmid":"27598200","id":"PMC_27598200","title":"A Novel Zak Knockout Mouse with a Defective Ribotoxic Stress Response.","date":"2016","source":"Toxins","url":"https://pubmed.ncbi.nlm.nih.gov/27598200","citation_count":9,"is_preprint":false},{"pmid":"27207779","id":"PMC_27207779","title":"Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27207779","citation_count":9,"is_preprint":false},{"pmid":"32688284","id":"PMC_32688284","title":"ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/32688284","citation_count":9,"is_preprint":false},{"pmid":"27655071","id":"PMC_27655071","title":"Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery.","date":"2016","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27655071","citation_count":8,"is_preprint":false},{"pmid":"35276386","id":"PMC_35276386","title":"Targeted inhibition of ZAK ameliorates renal interstitial fibrosis.","date":"2022","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35276386","citation_count":8,"is_preprint":false},{"pmid":"38451290","id":"PMC_38451290","title":"Heterozygous MAP3K20 variants cause ectodermal dysplasia, craniosynostosis, sensorineural hearing loss, and limb anomalies.","date":"2024","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38451290","citation_count":7,"is_preprint":false},{"pmid":"29374956","id":"PMC_29374956","title":"Antitumorigenic Effects of ZAKβ, an Alternative Splicing Isoform of ZAK.","date":"2018","source":"The Chinese journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29374956","citation_count":7,"is_preprint":false},{"pmid":"23607596","id":"PMC_23607596","title":"Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.","date":"2013","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/23607596","citation_count":7,"is_preprint":false},{"pmid":"19272173","id":"PMC_19272173","title":"RhoGDIbeta-induced hypertrophic growth in H9c2 cells is negatively regulated by ZAK.","date":"2009","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/19272173","citation_count":7,"is_preprint":false},{"pmid":"37547289","id":"PMC_37547289","title":"Two antisense RNAs-AFAP1-AS1 and MLK7-AS1-promote colorectal cancer progression by sponging miR-149-5p and miR-485-5p.","date":"2023","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/37547289","citation_count":6,"is_preprint":false},{"pmid":"33968726","id":"PMC_33968726","title":"Long Noncoding RNA MLK7-AS1 Promotes Non-Small-Cell Lung Cancer Migration and Invasion via the miR-375-3p/YWHAZ Axis.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33968726","citation_count":6,"is_preprint":false},{"pmid":"27127137","id":"PMC_27127137","title":"A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer.","date":"2016","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27127137","citation_count":6,"is_preprint":false},{"pmid":"27783979","id":"PMC_27783979","title":"A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling.","date":"2016","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27783979","citation_count":5,"is_preprint":false},{"pmid":"14521931","id":"PMC_14521931","title":"Effect of C-terminal truncations on MLK7 catalytic activity and JNK activation.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14521931","citation_count":5,"is_preprint":false},{"pmid":"32397561","id":"PMC_32397561","title":"Selective Activation of ZAK β Expression by 3-Hydroxy-2-Phenylchromone Inhibits Human Osteosarcoma Cells and Triggers Apoptosis via JNK Activation.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32397561","citation_count":5,"is_preprint":false},{"pmid":"28809879","id":"PMC_28809879","title":"Zak phase induced multiband waveguide by two-dimensional photonic crystals.","date":"2017","source":"Optics letters","url":"https://pubmed.ncbi.nlm.nih.gov/28809879","citation_count":5,"is_preprint":false},{"pmid":"22146853","id":"PMC_22146853","title":"Transient global cerebral ischemia induces up-regulation of MLTKα in hippocampal CA1 neurons.","date":"2011","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/22146853","citation_count":4,"is_preprint":false},{"pmid":"37427997","id":"PMC_37427997","title":"Myofibrillar myopathy hallmarks associated with ZAK deficiency.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37427997","citation_count":3,"is_preprint":false},{"pmid":"32266845","id":"PMC_32266845","title":"Rare missense variant p.Ala505Ser in the ZAK protein observed in a patient with split-hand/foot malformation from a non-consanguineous pedigree.","date":"2020","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/32266845","citation_count":3,"is_preprint":false},{"pmid":"33153490","id":"PMC_33153490","title":"Retraction Note: Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33153490","citation_count":2,"is_preprint":false},{"pmid":"35093924","id":"PMC_35093924","title":"Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients With Incurable Pancreatic Cancer.","date":"2022","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35093924","citation_count":2,"is_preprint":false},{"pmid":"31060033","id":"PMC_31060033","title":"Studies of pharmacokinetics in beagle dogs and drug-drug interaction potential of a novel selective ZAK inhibitor 3h for hypertrophic cardiomyopathy treatment.","date":"2019","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/31060033","citation_count":2,"is_preprint":false},{"pmid":"40727254","id":"PMC_40727254","title":"Polypharmacology-Driven Discovery of ZAK-I-57: A Potent Multi-Targeted Benzoxazinone Small Molecule for Hepatocellular Carcinoma Therapy.","date":"2025","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/40727254","citation_count":1,"is_preprint":false},{"pmid":"41192115","id":"PMC_41192115","title":"Inhibition the MAP3K20-mediated ribotoxic stress response pathway downregulates M1 macrophage polarization in ulcerative colitis.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41192115","citation_count":0,"is_preprint":false},{"pmid":"42031169","id":"PMC_42031169","title":"An inhibitor of GCN2 and the integrated stress response directly targets ZAK protein kinase to limit cytotoxicity.","date":"2026","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/42031169","citation_count":0,"is_preprint":false},{"pmid":"41912913","id":"PMC_41912913","title":"BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.","date":"2026","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/41912913","citation_count":0,"is_preprint":false},{"pmid":"41064052","id":"PMC_41064052","title":"Confirmation of the Hotspot Variant in MAP3K20 Responsible for Deafness, Ectodermal Dysplasia, Craniosynostosis, Ectrodactyly, and Skeletal Anomaly Spectrum.","date":"2025","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/41064052","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.16.643544","title":"Distinct Co-Methylation Patterns in African and European Populations and Their Genetic Associations","date":"2025-03-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.16.643544","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.15.623822","title":"Pan-Cancer Genetic Profiles of Mitotic DNA Integrity Checkpoint Protein Kinases","date":"2024-11-15","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.15.623822","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.10.658914","title":"Stalled translation on transcripts cleaved by RNase L activates signaling important for innate immunity","date":"2025-06-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.10.658914","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.22.689755","title":"ZAKα is a sensor of mRNA stasis at the ribosomal exit channel","date":"2025-11-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.22.689755","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33248,"output_tokens":9390,"usd":0.120297,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19896,"output_tokens":4746,"usd":0.109065,"stage2_stop_reason":"end_turn"},"total_usd":0.229362,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"MLTK (MAP3K20) was identified as a novel MAPKKK with two alternatively spliced isoforms, MLTKα and MLTKβ. Both isoforms activate ERK, JNK/SAPK, p38, and ERK5 pathways when overexpressed. Both are activated by osmotic shock via autophosphorylation. MLTKα (but not MLTKβ) expression disrupts actin stress fibers and causes morphological changes; a kinase-dead MLTKα does not, and p38 inhibition blocks these effects, placing p38 downstream of MLTKα in actin regulation.\",\n      \"method\": \"Overexpression in cells, kinase-dead mutant analysis, pharmacological p38 inhibition, SDS-PAGE mobility shift assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (overexpression, kinase-dead mutant, pharmacological inhibition) in a single lab; foundational characterization paper\",\n      \"pmids\": [\"11042189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ZAK protein contains a kinase catalytic domain, a leucine-zipper, and a sterile-alpha motif (SAM), forms homodimers or oligomers in mammalian cells, and specifically activates the JNK/SAPK pathway and NF-κB transcription factor upon overexpression. Overexpression induces apoptosis in hepatoma cells.\",\n      \"method\": \"Cloning, overexpression in mammalian cells, Western blot for homodimerization/oligomerization, reporter assays for NF-κB and JNK/SAPK\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional readouts (dimerization, pathway activation, apoptosis) in a single lab with direct overexpression experiments\",\n      \"pmids\": [\"10924358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ZAK activates JNK/SAPK via MKK7 but not MKK4: co-expression of dominant-negative MKK7 (but not dominant-negative MKK4) significantly attenuates ZAK-induced JNK/SAPK activation. ZAK expression (but not kinase-dead ZAK) disrupts actin stress fibers. ZAK expression increases the G2/M cell population and decreases cyclin E levels.\",\n      \"method\": \"Dominant-negative co-expression, kinase-dead mutant, Western blot for cyclin E, flow cytometry for cell cycle\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via dominant-negative constructs and kinase-dead mutant, single lab, multiple readouts\",\n      \"pmids\": [\"12220515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PKNα phosphorylates MLTKα (MAP3K20) in vitro and this phosphorylation enhances MLTKα kinase activity. A kinase-negative PKNα mutant inhibits osmotic shock-induced MLTKα mobility shift. PKNα physically associates with MLTKα, MKK6, and p38γ, suggesting PKNα functions as both an upstream activator of MLTKα and a scaffold for the p38γ MAPK signaling pathway.\",\n      \"method\": \"In vitro kinase assay, kinase-negative mutant expression, co-immunoprecipitation, SDS-PAGE mobility shift\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus co-IP plus mutant analysis in single lab, multiple orthogonal methods establishing PKNα as writer/activator of MLTKα\",\n      \"pmids\": [\"12761180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ZAK interacts with the novel zinc finger protein ZZaPK (identified by yeast two-hybrid). ZZaPK overexpression promotes cell re-entry into the cell cycle by increasing E2F expression and cyclin E/CDK2 activity, counteracting ZAK-mediated cell cycle arrest. ZAK is proposed to suppress ZZaPK function upstream.\",\n      \"method\": \"Yeast two-hybrid, co-expression studies, Western blot for E2F and cyclin E\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid interaction, single lab, limited functional validation of interaction mechanism\",\n      \"pmids\": [\"12535642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The leucine zipper domain of MLK7 (MAP3K20) is required for full catalytic activity and is necessary for full pathway (JNK) activation: C-terminal deletion mutants lacking the leucine zipper retain only ~25% catalytic activity. However, sequence in residues 322–436 (beyond the leucine zipper) is necessary for full JNK pathway activation, as deletion of this region abolishes JNK activation.\",\n      \"method\": \"C-terminal deletion mutants, in vitro kinase assay for specific activity, co-transfection with JNK\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assays with nested deletion mutants, single lab, multiple constructs tested\",\n      \"pmids\": [\"14521931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZAK overexpression in H9c2 cardiomyoblast cells induces hypertrophic growth features including increased cell size, elevated atrial natriuretic factor (ANF) expression, and increased actin fiber organization, establishing ZAK as a positive mediator of cardiac hypertrophy.\",\n      \"method\": \"Overexpression in H9c2 cells, cell size measurement, ANF reporter/expression, actin staining\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct overexpression with multiple hypertrophy readouts, single lab\",\n      \"pmids\": [\"15485649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TGF-β induces cardiac hypertrophy via a ZAK→MKK7→ANF signaling axis. Dominant-negative ZAK inhibits TGF-β-induced hypertrophic features (cell size, ANF expression, actin organization). Dominant-negative MKK7 blocks both TGF-β- and ZAK-induced ANF expression. JNK inhibitor SP600125 had little effect, distinguishing a JNK-independent MKK7-mediated pathway downstream of ZAK.\",\n      \"method\": \"Dominant-negative ZAK and MKK7 constructs, pharmacological JNK inhibitor, ANF expression assay, cell size measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis by dominant-negative constructs and pharmacological inhibition, single lab, multiple readouts\",\n      \"pmids\": [\"15465036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Transgenic mice with cardiac-specific overexpression of MLK7 (MAP3K20) develop myocardial fibrosis, hypertrophy, impaired systolic function, diastolic dysfunction, and increased mortality upon isoproterenol administration. Isoproterenol-induced activation of JNK and p38 (but not ERK) is significantly greater in MLK7 Tg mice, establishing that MLK7 simultaneously activates JNK and p38 in vivo in cardiac stress.\",\n      \"method\": \"Transgenic mouse generation, hemodynamic analysis, histology, Western blot for MAPK phosphorylation, isoproterenol challenge\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic model with cardiac-specific overexpression, multiple orthogonal readouts (hemodynamics, histology, signaling), clear phenotypic consequence\",\n      \"pmids\": [\"15350844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ZAK (a ZAK isoform) is the MAP3K that transduces the ribotoxic stress response (RSR) from intoxicated ribosomes to SAPKinase activation following Shiga toxin 2 and ricin treatment. A ZAK-specific inhibitor (DHP-2) and siRNA knockdown of ZAK both diminish Stx2/ricin-induced SAPKinase activation and block upregulation of proinflammatory cytokine IL-8.\",\n      \"method\": \"ZAK-specific small molecule inhibitor (DHP-2), siRNA knockdown, Western blot for SAPK phosphorylation, IL-8 cytokine measurement\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two orthogonal loss-of-function approaches (inhibitor + siRNA) with multiple readouts (kinase activation, cytokine production, cell viability)\",\n      \"pmids\": [\"18331592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RhoGDIβ physically interacts with ZAK and is phosphorylated by ZAK in vitro. This phosphorylation negatively regulates RhoGDIβ functions. Conversely, the ZAK–RhoGDIβ interaction maintains ZAK in an inactive hypophosphorylated form, revealing mutual negative regulation. ZAK knockdown in ZAK/RhoGDIβ co-expressing cells restores full RhoGDIβ function.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase/phosphorylation assay, siRNA knockdown, Western blot\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation assay plus co-IP plus siRNA rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19272173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZAK overexpression in H9c2 cells increases MMP-2 activity via JNK1/2 and p38 signaling, and reduces MMP-9 activity by increasing TIMP-1/2 expression, potentially contributing to cardiac fibrosis.\",\n      \"method\": \"Overexpression in H9c2 cells, zymography for MMP-2/9 activity, Western blot for TIMP-1/2, pathway inhibitor studies\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct overexpression with enzymatic activity readouts and pathway inhibitors, single lab\",\n      \"pmids\": [\"19184368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZAK is required for doxorubicin-induced SAPK activation and apoptosis in HaCaT keratinocytes (but not HeLa cells). siRNA-mediated knockdown of ZAK or ZAK inhibitors (sorafenib, nilotinib) block doxorubicin-induced proinflammatory and apoptotic responses, establishing ZAK as the upstream MAP3K in doxorubicin-triggered ribotoxic stress response.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition (sorafenib, nilotinib), Western blot for SAPK/ZAK, cell viability/apoptosis assays\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent loss-of-function methods (siRNA + two inhibitors) with multiple downstream readouts in defined cell contexts\",\n      \"pmids\": [\"20559024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZAK overexpression in lung cancer cells suppresses proliferation via ERK and JNK pathway activation in an AP-1-dependent manner. ZAK silencing reduces phospho-ERK and phospho-JNK without affecting p38. c-Jun RNAi reverses ZAK-mediated growth suppression and AP-1 activity. ZAK activates JNK→c-Jun and ERK→c-Fos to regulate AP-1.\",\n      \"method\": \"Overexpression, siRNA knockdown, ERK/JNK pathway inhibitors, AP-1 reporter (SEAP assay), c-Jun RNAi, Western blot, in vivo tumor xenograft\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple gain/loss-of-function approaches with pathway inhibitors and reporter assays, single lab\",\n      \"pmids\": [\"20331627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MLTK (MAP3K20) plays an essential role in chondrogenesis by triggering Sox9-dependent induction of Sox6 expression. Knockdown of MLTK in Xenopus embryos causes loss of craniofacial cartilages without defects in neural crest development. Sox6 knockdown phenocopies MLTK knockdown. Ectopic MLTK expression induces Sox6 in a Sox9-dependent manner. p38 and JNK pathways function downstream of MLTK during chondrogenesis.\",\n      \"method\": \"Morpholino knockdown in Xenopus, ectopic expression, in situ hybridization, pharmacological p38/JNK inhibition\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockdown with phenotype, ectopic expression rescue, pathway epistasis, Sox9-dependency test, multiple orthogonal methods in Xenopus model\",\n      \"pmids\": [\"22764049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ZAK is required for doxorubicin-induced activation of JNK and p38 MAPK in mouse primary macrophages. Using ZAK-deficient mouse macrophages, ZAK deficiency prevents doxorubicin-mediated phosphorylation of JNK and p38 and blocks expression of IL-1β, IL-6 and CXCL1. Nilotinib, ponatinib, and sorafenib suppress these effects pharmacologically.\",\n      \"method\": \"ZAK-deficient mouse macrophages (genetic KO), pharmacological inhibitors, Western blot for MAPK phosphorylation, qRT-PCR and ELISA for cytokines, in vivo co-administration in mice\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model plus pharmacological validation, in vitro and in vivo, multiple orthogonal readouts\",\n      \"pmids\": [\"23114643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Sorafenib suppresses UV-induced apoptosis in cells by off-target inhibition of ZAK, thereby preventing ZAK-mediated JNK activation. This JNK suppression is independent of the ERK pathway, identifying ZAK inhibition as a mechanism of sorafenib adverse effects (cutaneous SCC development).\",\n      \"method\": \"Pharmacological inhibition, Western blot for JNK phosphorylation, apoptosis assays, comparison with ERK pathway\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological evidence with pathway-specific readouts, single lab, mechanistic claim supported by context-specific inhibition experiments\",\n      \"pmids\": [\"24170769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ZAK activates MKK4 at the MAPKK level and is upstream of a ZAK→MKK4→JNK→TGFβ2 signaling cascade activated by the anticancer compound BA-TPQ in cancer cells but not normal cells.\",\n      \"method\": \"Phosphorylation analysis, pathway inhibitors (SP600125 for JNK, SD-208 for TGFβ), Western blot, mRNA quantification\",\n      \"journal\": \"Current cancer drug targets\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pharmacological pathway inference without direct biochemical reconstitution of ZAK→MKK4 step\",\n      \"pmids\": [\"23607596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZAK-mediated cardiomyocyte hypertrophy requires p38 and JNK pathway activation and nuclear translocation of GATA4 and c-Jun transcription factors, without involvement of ERK or NFATc3. A dominant-negative ZAK shows no effect on p38/JNK signaling. JNK1/2 and p38 inhibitors significantly suppress ZAK-induced BNP expression.\",\n      \"method\": \"Doxycycline-inducible Tet-on ZAK WT and DN expression systems, pathway inhibitors, Western blot for MAPK and transcription factors, nuclear translocation imaging\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible expression system with kinase-dead control plus pharmacological inhibitors, multiple pathway readouts, single lab\",\n      \"pmids\": [\"25869677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZAK (both isoforms ZAKα and ZAKβ) is a key factor in cancer cell migration. ZAK depletion reduces cell motility; overexpression activates ERK, JNK, and p38 and increases cell motion. Kinase-dead mutants ZAKα K45M and ZAKβ K45M act as dominant negatives, suppressing MAPK activation and migration. ZAK constitutes an essential element of the EGF/ERK-dependent cell migration pathway.\",\n      \"method\": \"siRNA knockdown, kinase-dead mutant overexpression, ZAK inhibitor (nilotinib), migration assays, Western blot for MAPK phosphorylation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple loss-of-function approaches (siRNA, kinase-dead, inhibitor), pathway readouts, single lab\",\n      \"pmids\": [\"26522728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structure of ZAK kinase domain in complex with vemurafenib was solved, revealing a highly distorted P-loop conformation. Positional scanning peptide library analysis revealed unique substrate specificity with unprecedented preferences for histidine residues at positions -1 and +2 relative to the phosphoacceptor site.\",\n      \"method\": \"X-ray crystallography (co-crystal structure), positional scanning peptide library, clinical kinase inhibitor library screen\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional substrate specificity profiling, single study with multiple orthogonal methods\",\n      \"pmids\": [\"26999302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss-of-function mutations in the SAM domain of ZAK cause split-foot defects in humans. CRISPR/Cas9-mediated knockout of both Zak isoforms is embryonically lethal in mice, while SAM domain deletion induces complex hindlimb defects associated with down-regulation of Trp63 (a known SHFM disease gene), placing ZAK upstream of Trp63 in limb patterning.\",\n      \"method\": \"Human genetic analysis, CRISPR/Cas9 knockout/deletion in mouse, in situ hybridization for Zak expression in limbs, transcriptome analysis for Trp63\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO mouse model with domain-specific deletion, genetic epistasis via Trp63 downregulation, replication in two human families\",\n      \"pmids\": [\"26755636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In a novel ZAK knockout mouse, ricin-intoxicated macrophages from zak-/- mice fail to activate p38 and JNK1/2 and show decreased c-jun and cxcl-1 expression compared to wild-type. zak-/- mice show decreased duodenal damage following in vivo ricin challenge, confirming ZAK's essential role in the ribotoxic stress response in vivo.\",\n      \"method\": \"ZAK knockout mouse, Western blot for p38/JNK activation, qRT-PCR, blinded histopathology of duodenal tissue\",\n      \"journal\": \"Toxins\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with in vitro and in vivo phenotypic readouts, blinded histopathology, multiple molecular endpoints\",\n      \"pmids\": [\"27598200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZAK (MRK) protects tumor cells from radiation-induced cell death by regulating cell-cycle arrest after ionizing radiation. siRNA depletion of ZAK sensitizes medulloblastoma cells to radiation. A ZAK-specific irreversible small molecule inhibitor (M443) inhibits radiation-induced activation of p38 and Chk2 (downstream of ZAK) and radiosensitizes tumor cells but not normal brain cells.\",\n      \"method\": \"siRNA knockdown, small molecule ZAK inhibitor (M443, irreversible), Western blot for p38/Chk2, cell viability, orthotopic animal model\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological inhibition with pathway readouts, in vivo model, single lab\",\n      \"pmids\": [\"27207779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZAK kinase activity is required for canonical TGF-β/SMAD-dependent signaling: siRNA depletion of ZAK strongly inhibits TGF-β-dependent SMAD2/3 phosphorylation and SMAD binding element-driven luciferase activity. A ZAK inhibitor (DHP-2) dose-dependently activates a TGFβR-kinase activity reporter, blocks TGF-β-induced SMAD2/3 phosphorylation, and inhibits cancer cell invasion.\",\n      \"method\": \"siRNA knockdown, pharmacological ZAK inhibitor (DHP-2), bioluminescent kinase reporter (BTR), SMAD2/3 phosphorylation assay, SBE4-Luc reporter, invasion assay\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological inhibitor with multiple pathway readouts, single lab, two orthogonal loss-of-function methods\",\n      \"pmids\": [\"27783979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZAK-mediated EMT is associated with activation of ZEB1, suppression of epithelial splicing regulatory proteins (ESRPs), and a switch in CD44 isoform expression from epithelial CD44v8-9 to mesenchymal CD44s. ZAK depletion in mesenchymal cancer cells reverses EMT, increases drug sensitivity, and attenuates bone metastasis.\",\n      \"method\": \"cDNA overexpression screen, ZAK depletion (siRNA/shRNA), Western blot for EMT markers, CD44 isoform analysis, bone metastasis assay, transcriptomics\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain and loss of function with mechanistic readouts (ZEB1, ESRPs, CD44 isoform switch), single lab\",\n      \"pmids\": [\"29396440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ERβ directly binds ZAK under normal conditions (interaction shown by co-IP). ZAK overexpression reduces ZAK-ERβ association. ERβ overexpression blocks ZAK nuclear translocation via inhibition of SUMO-1 modification of ZAK, and suppresses ZAK-induced p-JNK, p-p38, c-Jun, and GATA-4 upregulation.\",\n      \"method\": \"Co-immunoprecipitation, transient transfection, Western blot for SUMO-1 modification, nuclear fractionation/localization assay\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP for direct interaction, SUMO-1 modification analysis, nuclear localization assay, single lab\",\n      \"pmids\": [\"29932238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZAKβ isoform has antitumorigenic properties opposite to ZAKα. High ZAKβ:ZAKα ratio activates cAMP/CREB1 signaling, reduces cyclooxygenase 2 and β-catenin, and inhibits anchorage-independent growth. Doxorubicin treatment switches endogenous expression from ZAKα to ZAKβ.\",\n      \"method\": \"Isoform-specific overexpression, soft agar anchorage-independent growth assay, Western blot, cAMP reporter assay, doxorubicin treatment\",\n      \"journal\": \"The Chinese journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific overexpression with functional and signaling readouts, single lab\",\n      \"pmids\": [\"29374956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Upon ribosome impairment (Rptor deletion, amino acid starvation, or low-dose cycloheximide), intestinal stem cells gain an Lgr5-negative fetal-like identity requiring ZAKα activation. Mechanistically, ZAKα activates YAP via SRC kinase to mediate this stem cell identity switch. ZAKα is thus identified as a critical mediator of ISC plasticity downstream of ribosome stress.\",\n      \"method\": \"Mouse intestinal organoids, conditional mouse knockouts, pharmacological ribosome impairment, Western blot for ZAKα/YAP/SRC, ISC identity markers (Lgr5, fetal markers), metabolic profiling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple ribosome impairment methods, mouse and organoid models, pathway epistasis (ZAKα→SRC→YAP), mechanistic and phenotypic readouts, replicated across perturbations\",\n      \"pmids\": [\"35918345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZAK overexpression in fibrotic kidney is in complex with Smad2/3 and TGF-β receptor I (TβRI). Silencing ZAK reduces Smad2/3 recruitment to TβRI and attenuates p38 MAPK and Smad signaling, reducing tubulointerstitial fibrosis in vivo.\",\n      \"method\": \"Co-immunoprecipitation of ZAK-Smad2/3-TβRI complex, ZAK siRNA knockdown, UUO mouse model, Western blot, pharmacological ZAK inhibitor (6p)\",\n      \"journal\": \"Translational research : the journal of laboratory and clinical medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP establishes complex membership, siRNA and inhibitor loss-of-function with in vivo validation, single lab\",\n      \"pmids\": [\"35276386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZAKβ isoform is the only isoform expressed in skeletal muscle and is activated by muscle contraction and cellular compression. Phosphoproteomics identified SYNPO2, BAG3, and Filamin C (FLNC) as ZAKβ substrates/interactors. ZAK deficiency leads to accumulation of mislocalized FLNC and BAG3 in muscle fibers, with exacerbation by endogenous muscle overloading, establishing ZAKβ as necessary for adaptive turnover of FLNC in response to mechanical stress.\",\n      \"method\": \"Phosphoproteomics, ZAK-deficient mice and zebrafish, immunofluorescence of human biopsy and mouse muscle, overloading model, histopathology\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics plus genetic KO in multiple organisms plus human biopsy, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37427997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Cryo-EM and biochemistry revealed that ZAK is constitutively recruited to ribosomes and, upon ribosome collisions, interactions between ZAK and ribosomal protein RACK1 enable activation by dimerization of its SAM domains at the collision interface. SERBP1, a ribosome-binding protein, negatively regulates ZAK by preventing constitutive activation. SAM domain variants (including a known pathogenic variant) can bypass the ribosome requirement for ZAK activation, confirming the SAM domain's key role in regulating kinase activity on and off the ribosome.\",\n      \"method\": \"Cryo-electron microscopy, biochemical reconstitution, SAM domain mutagenesis, co-immunoprecipitation for RACK1 and SERBP1 interactions\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure plus biochemical reconstitution plus mutagenesis, multiple orthogonal methods, establishes mechanistic blueprint for ZAK activation\",\n      \"pmids\": [\"41261136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"BCR::ABL1 inhibition in CML cells induces ribosome collisions, generating collided ribosomes that trigger ZAK-dependent p38 activation and apoptosis. Mechanistically, BCR::ABL1 inhibition activates the mTOR-EEF2K pathway to phosphorylate EEF2, slowing translation elongation and generating nuclease-resistant collided ribosomes upstream of ZAK. Loss of ZAK function reduces the cytotoxic effects of BCR::ABL1 inhibitors.\",\n      \"method\": \"ZAK loss-of-function (siRNA/CRISPR), ribosome profiling/nuclease protection assay for collided ribosomes, Western blot for p38/EEF2 phosphorylation, primary CML patient cells, pharmacological translation modulation\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic ZAK loss-of-function, ribosome collision biochemical assay, patient primary cells, mechanistic pathway defined (mTOR-EEF2K-EEF2→ribosome collision→ZAK→p38→apoptosis)\",\n      \"pmids\": [\"41912913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GCN2iB, widely used as a GCN2/ISR inhibitor, is a direct inhibitor of ZAK kinase. Biochemical measurements, cell-based assays, and structural modeling demonstrate that GCN2iB inhibits ZAK, dampening stress-induced JNK and p38 activation. This off-target ZAK inhibition masks cytotoxic consequences normally associated with GCN2 inhibition.\",\n      \"method\": \"Biochemical kinase assay, cell-based MAPK phosphorylation assays, structural modeling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical inhibition assay plus structural modeling plus cell-based validation, single study\",\n      \"pmids\": [\"42031169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZAKα dynamically monitors the mRNA exit channel of elongating ribosomes for mRNA stasis via direct interactions with ribosomal proteins RACK1 and RPS27 and with 18S rRNA helix-26. Four mRNA-binding peptides in ZAKα span across the path of ribosome-exiting mRNA. Progressive elongation threads ZAKα off the ribosome, while mRNA stasis stabilizes the interaction. Prolonged binding is associated with sequestration of the inhibitory SAM domain on RACK1, allowing transient ZAKα dimerization, activation loop trans-autophosphorylation, and RSR activation.\",\n      \"method\": \"AlphaFold3 structural prediction, RNA crosslinking and immunoprecipitation (CLIP), biochemical interaction mapping, mutagenesis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — CLIP plus structural prediction plus mutagenesis, preprint not yet peer-reviewed, but orthogonal to and consistent with published cryo-EM data\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"MAP3K20 (ZAK/MLTK) is a MAP kinase kinase kinase with two isoforms (ZAKα/MLTKα and ZAKβ/MLTKβ) that functions as a central sensor of ribotoxic stress: ZAKα is constitutively recruited to elongating ribosomes via RACK1 and RPS27 interactions and is activated by SAM-domain dimerization at ribosome collision interfaces (negatively regulated by SERBP1), whereupon it phosphorylates and activates downstream MAPKs p38 and JNK (via MKK7 preferentially) to drive proinflammatory cytokine production, apoptosis, cell cycle arrest, and stem cell identity changes; it also regulates cardiac hypertrophy (via p38/JNK→GATA4/c-Jun), chondrogenesis (via p38/JNK→Sox6 induction), cell migration (via ERK/JNK), EMT (via ZEB1/ESRP/CD44 isoform switching), and TGF-β canonical signaling (by forming a complex with Smad2/3 and TβRI), while ZAKβ is the mechanosensitive isoform in skeletal muscle that mediates adaptive turnover of Filamin C under mechanical stress.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MAP3K20 (ZAK/MLTK) is a MAP kinase kinase kinase that operates as the central sensor of ribotoxic stress, transducing damage at the ribosome to stress-activated MAPK output [#9]. The protein is expressed as two alternatively spliced isoforms (ZAK\\u03b1/MLTK\\u03b1 and ZAK\\u03b2/MLTK\\u03b2) that activate JNK/SAPK, p38, ERK and NF-\\u03baB and are activated by osmotic shock through autophosphorylation [#0, #1]. Its architecture\\u2014kinase domain, leucine zipper required for full catalytic activity, and a sterile-alpha (SAM) domain mediating homo-oligomerization\\u2014defines its activation logic [#1, #5]. ZAK\\u03b1 is constitutively recruited to elongating ribosomes through interactions with RACK1, RPS27 and 18S rRNA, monitoring the mRNA exit channel; ribosome collisions promote SAM-domain dimerization at the collision interface, trans-autophosphorylation, and ribotoxic stress response activation, a step negatively regulated by SERBP1, while pathogenic SAM-domain variants bypass the ribosome requirement [#31]. Downstream, ZAK preferentially routes JNK activation through MKK7 and simultaneously activates p38 in vivo, driving proinflammatory cytokine production (IL-8, IL-1\\u03b2, IL-6, CXCL1), apoptosis, and cell-cycle arrest in response to ribotoxic insults including Shiga toxin, ricin and doxorubicin [#2, #8, #9, #15, #22]. Beyond stress sensing, ZAK acts as a positive mediator of cardiac hypertrophy and fibrosis via p38/JNK\\u2192GATA4/c-Jun [#7, #8, #18], is essential for chondrogenesis through Sox9-dependent Sox6 induction [#14], promotes cancer cell migration, EMT and invasion [#19, #25], and participates in canonical TGF-\\u03b2/SMAD signaling by complexing with Smad2/3 and T\\u03b2RI [#24, #29]. The ZAK\\u03b2 isoform is the mechanosensitive species in skeletal muscle, activated by contraction and compression and required for adaptive turnover of Filamin C with BAG3 and SYNPO2 under mechanical stress [#30]. Loss-of-function SAM-domain mutations cause human split-foot/limb defects, placing ZAK upstream of Trp63 in limb patterning [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that MAP3K20 is a genuine MAP3K answered whether a new node feeds the stress MAPK network; it defined two isoforms and their upstream-kinase behavior.\",\n      \"evidence\": \"cloning, overexpression with kinase-dead mutants, and pharmacological p38 inhibition in mammalian cells\",\n      \"pmids\": [\"11042189\", \"10924358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Activation relied on overexpression, not endogenous stimuli\", \"Physiological activating signals beyond osmotic shock unknown\", \"Isoform-specific functions not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defining the immediate downstream MAPKK answered how ZAK channels JNK activation and linked it to cell-cycle control.\",\n      \"evidence\": \"dominant-negative MKK7 vs MKK4 epistasis, kinase-dead mutant, flow cytometry and cyclin E blots\",\n      \"pmids\": [\"12220515\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MKK7 specificity tested only by dominant-negative, not direct phosphorylation\", \"Mechanism of G2/M arrest not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identifying PKN\\u03b1 as a direct activator/scaffold addressed how ZAK kinase activity is itself regulated upstream.\",\n      \"evidence\": \"in vitro kinase assay, kinase-negative PKN\\u03b1, and co-IP of MLTK\\u03b1/MKK6/p38\\u03b3\",\n      \"pmids\": [\"12761180\", \"14521931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PKN\\u03b1 regulation operates at endogenous levels untested\", \"Relationship of PKN\\u03b1 input to ribotoxic activation unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placing ZAK as the MAP3K of the ribotoxic stress response answered what kinase couples damaged ribosomes to SAPK and cytokine output\\u2014its defining role.\",\n      \"evidence\": \"ZAK-specific inhibitor and siRNA after Shiga toxin/ricin, with SAPK and IL-8 readouts\",\n      \"pmids\": [\"18331592\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How damaged ribosomes are physically sensed not yet defined\", \"Direct ribosome interaction not shown at this stage\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extending ribotoxic stress to chemotherapy and context dependence clarified when ZAK governs apoptosis versus proliferation.\",\n      \"evidence\": \"siRNA and multiple inhibitors in keratinocytes vs HeLa; ERK/JNK/AP-1 readouts and xenografts in lung cancer cells\",\n      \"pmids\": [\"20559024\", \"20331627\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type basis of opposing outcomes unexplained\", \"Direct substrates of ERK vs JNK branches not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining the cardiac and migration outputs answered what physiological processes ZAK MAPK signaling drives beyond stress.\",\n      \"evidence\": \"inducible WT/dominant-negative ZAK, kinase-dead mutants, pathway inhibitors, transgenic and H9c2 systems\",\n      \"pmids\": [\"25869677\", \"26522728\", \"15350844\", \"15465036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between ribotoxic sensing and cardiac/migration roles unclear\", \"Endogenous activating signal in cardiomyocytes undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Structural and genetic work answered both the catalytic basis of ZAK substrate selection and its in vivo developmental requirement.\",\n      \"evidence\": \"kinase-domain crystal structure with peptide-library specificity profiling, and CRISPR SAM-deletion mice with human SHFM family genetics linking ZAK upstream of Trp63\",\n      \"pmids\": [\"26999302\", \"26755636\", \"27598200\", \"22764049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates matching the histidine-preference motif not identified\", \"How SAM-domain loss perturbs limb patterning at the signaling level unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolving isoform divergence and EMT control answered why ZAK\\u03b1 and ZAK\\u03b2 can produce opposing tumor phenotypes.\",\n      \"evidence\": \"isoform-specific overexpression, soft-agar growth, ZEB1/ESRP/CD44 isoform analysis, and ER\\u03b2 co-IP/SUMO-1 modulation of nuclear translocation\",\n      \"pmids\": [\"29396440\", \"29374956\", \"29932238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular determinant of ZAK\\u03b1 vs ZAK\\u03b2 output not defined\", \"Direct effectors of EMT splicing switch unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking ZAK\\u03b1 to ribosome-stress-driven stem cell plasticity and TGF-\\u03b2 fibrosis expanded the downstream physiology of the ribotoxic sensor.\",\n      \"evidence\": \"intestinal organoids/conditional KO with ZAK\\u03b1\\u2192SRC\\u2192YAP epistasis, and ZAK\\u2013Smad2/3\\u2013T\\u03b2RI co-IP with UUO mouse model\",\n      \"pmids\": [\"35918345\", \"35276386\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ribosome stress is decoded into a YAP versus MAPK output unclear\", \"Direct phosphorylation events in the SMAD complex not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defining ZAK\\u03b2 as the muscle mechanosensor answered the distinct physiological function of the second isoform.\",\n      \"evidence\": \"phosphoproteomics identifying SYNPO2/BAG3/FLNC, ZAK-deficient mice and zebrafish, and human biopsy immunofluorescence with overloading\",\n      \"pmids\": [\"37427997\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct phosphorylation of FLNC not biochemically confirmed\", \"How mechanical force activates ZAK\\u03b2 mechanistically unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Cryo-EM and channel-monitoring models answered the long-standing question of how ZAK\\u03b1 physically senses ribosome collisions and mRNA stasis to trigger activation.\",\n      \"evidence\": \"cryo-EM, biochemical reconstitution and SAM mutagenesis (RACK1/SERBP1); plus CLIP and AlphaFold3 mapping of RACK1/RPS27/18S helix-26 contacts (preprint)\",\n      \"pmids\": [\"41261136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How collision-driven dimerization is timed and reversed not fully defined\", \"Quantitative threshold of collisions required for activation unknown\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Connecting oncogene inhibition to ribosome collisions and clarifying inhibitor off-target effects refined the therapeutic logic of ZAK targeting.\",\n      \"evidence\": \"ZAK loss-of-function with ribosome collision assays in CML cells defining mTOR-EEF2K-EEF2\\u2192collision\\u2192ZAK\\u2192p38; biochemical and structural demonstration that GCN2iB directly inhibits ZAK\",\n      \"pmids\": [\"41912913\", \"42031169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of collision-driven ZAK cytotoxicity across drug classes untested\", \"Selectivity of clinical ZAK inhibitors incompletely characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the same ribosome-collision-activated kinase is wired to such divergent outputs\\u2014cytokine/apoptosis, cardiac hypertrophy, chondrogenesis, EMT, stem-cell identity, and muscle mechanostructural turnover\\u2014remains the central open question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological direct substrates beyond MAPKKs largely unidentified\", \"Determinants selecting downstream output by cell type and isoform unknown\", \"Activation mechanism of ZAK\\u03b2 mechanosensing not structurally defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 3, 9, 20]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 5, 20]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [9, 31, 34]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [9, 31, 34]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005840\", \"supporting_discovery_ids\": [31, 34]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 9, 24]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [9, 31, 32]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [31, 32, 34]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 12, 32]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [14, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 15, 22]}\n    ],\n    \"complexes\": [\n      \"ZAK-Smad2/3-T\\u03b2RI complex\",\n      \"ribosome (ZAK\\u03b1-RACK1-RPS27)\"\n    ],\n    \"partners\": [\n      \"RACK1\",\n      \"RPS27\",\n      \"SERBP1\",\n      \"MKK7\",\n      \"PKN\\u03b1\",\n      \"SMAD2/3\",\n      \"ESR2\",\n      \"FLNC\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}